

Artificial intelligence Applications in Gastrointestinal Pathology

Benjamin J. Swanson MD PhD

Associate Professor of Pathology, Microbiology, & Immunology

University of Nebraska Medical Center

Director of Pathology Informatics and Digital Innovation



University of Nebraska
Medical Center

Disclosure:

Dr. Swanson owns stock and serves on the Scientific Advisory Board for Cogen Bioscience

Dr. Swanson lectures for the France Foundation/ASCP/ACCC (CME/AMA) on biomarker testing in colorectal carcinoma





Outline:

Opening Questions

Digital pathology

Artificial intelligence

General overview of applications in Surgical Pathology & GI

2 examples of research applications in GI Path→ future

Summary (opportunities, challenges)

Closing questions

What is a clinically validated example of AI an application in GI Path?



- A) Pancreas cancer detection in core biopsies
- B) Metastasis detection within lymph nodes of colorectal cancer resection specimens
- C) Grading of dysplasia in Barrett's esophagus
- D) Lymph node prediction in T1 polypectomy specimens
- E) Eosinophil quantitation in esophageal biopsies

What are current examples of AI applications in GI Path?

Answer:

B) Metastasis detection within lymph nodes of colorectal cancer resection specimens



What are the minimum hardware and software needs to perform clinically validated AI in Surgical Pathology?



What are the minimum hardware and software needs to perform clinically validated AI in Surgical Pathology?



WSI scanners

Image management software

PACS (picture archiving and communication system)

Validated AI software

Current State of Digital Pathology Scanning at the University of Nebraska (UNMC)



2 Leica GT450s



Maggie Sindelar
Lead Digital Pathology
Histotech

Currently scanned cases:

- Placenta
 - Autopsy
 - Transplant biopsies
 - Cardiovascular
 - Retrospective cases (tumor boards, consults, education)
- ~80 slides a day
~1,500-2,000 slides/month



UNMC's Digital Pathology Future: Fully Digital



GT450





Image Management Software
Must be scanner agnostic
Must be AI/ML agnostic

AI/ML integration



Storage (cloud, hot, cold, on-site, etc.)



Integration with LIS/EMR

Other Factors to Consider When Deploying Digital Pathology



Data architecture plan (on-premise, cloud, hot versus cold)

- Storage is expensive, most pathology departments that have gone fully digital have storage requirements in the petabytes

Who is going to load the scanners? Will need to have additional FTEs

How is your histology AP operations going to function/change to have minimal impact on turn around time?

How is your laboratory information system (LIS) support staff structured? Who will handle software and hardware issues?

\$\$\$\$\$\$\$\$

A Few Regional Institutions that Have Gone Fully Digital for Surgical Pathology



Memorial Sloan Kettering
Cancer Center





Apple and a PC

Circa 1985

Advantages of Primary Digital Signout



Remote consultation

Archiving slides for teaching

Tumor boards and associated conferences

Application to research

Only way to directly implement into AI algorithms

Business growth development: Technical only, international consults, etc.



Challenges in GI Pathology

High work volumes

Diagnosis complexity

Tedious/repetitive tasks (like counting eosinophils)

Difficult to standardize biomarkers (Ki-67, Her2, PD-L1 etc.)

Grading dysplasia (Barrett's, IBD)


Limitations to Timely and Accurate GI Pathologic Diagnoses in 2024



Nationwide shortage of Pathologists

Differences in Pathologist's skills,
diagnostic thresholds, fellowship
training, experience

Availability of ancillary molecular and
immunohistochemical studies



Inspired and partially adapted from: Lui et al. "Applications of Artificial Intelligence in Breast Pathology" Arch. Pathol. Lab Med. 147, September 2023

Potential Clinical Applications of AI in GI Pathology Signout



Pre-screening difficult biopsies for cancer/dysplasia

- Example: Identification of H. pylori

Performing rudimentary/tedious tasks

- -Example: counting eosinophils
- Identifying micrometastasis in lymph nodes

Standardization of biomarkers

- Example: Ki-67

Predicting recurrence/chemoresistance/genetic profiles from WSI



Overview of Artificial Intelligence

Machine learning is a type of artificial intelligence

Deep learning is a type of machine learning

Generative AI is a type of deep learning

Transformers and large language models are part of generative AI

Chat GPT is a kind of large language



Machine Learning and Deep Learning



Is a subfield of artificial intelligence


- ML develops algorithms to learn repetitive data patterns from a large data set, then matches new cases to the learned data patterns


Deep learning is a subset of Machine learning

- Uses artificial neural networks composed of multiple layers (input layer, hidden layers, output layers) to extract progressively higher level features from data.
- The neural network learns data patterns by generating multiple hidden variables from data and also learns hierarchical representation of data that can't easily be recognized by humans.
- Deep learning includes supervised learning, unsupervised learning, semisupervised learning and transfer learning
- Compared to conventional ML, DL is simpler to conduct, performs with high-precision, and is cost-effective

Deep convolutional neural networks, a type of DL algorithm

- Has shown superiority in image recognition and analysis





From: Yoshida, H. et al.
 "Requirements for implementation of artificial intelligence in the practice of gastrointestinal pathology" *World J Gastroenterol* 2021 June 7; 27(21): 2818-2833





OpenVMS Compaq VAX
7000

Circa 1995

Current Clinically Validated AI Applications in Surgical Pathology



Paige[®]



aiforia[®]

AI for image analysis



Clinical Application in the US

Any software solution should be developed under the FDA's Quality System Regulation and Good Machine Learning Practices.



Current AI Applications in the United States



A single prostate algorithm currently FDA approved
Some of the "clinically validated" (as advertised on a company's website) algorithms have been approved in the European Union (CE IVD) but don't yet have FDA approval
-->Therefore, these would be considered for research only use only in the US


09/21/2021	DEN200080	Paige Prostate	Paige.AI	Pathology	QPN
05/17/2012	K120489	Tissue of Origin Test Kit FFPE	Pathwork Diagnostics, Inc.	Pathology	QIW

From: <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices>



11/19/2021	K211328	EndoScreener	Chengdu Wision Medical Device Co., LTD.	Gastroenterology & Urology	QNP
07/23/2021	K211951	GI Genius	Cosmo Artificial Intelligence - AI Ltd	Gastroenterology & Urology	QNP
04/09/2021	DEN200055	GI Genius	Cosmo Artificial Intelligence - AI, Ltd.	Gastroenterology-Urology	QNP
11/25/2019	K190529	SOZO	ImpediMed Limited	Gastroenterology-Urology	QJB
04/16/2019	K180128	:SOZO	ImpediMed Limited	Gastroenterology-Urology	OBH
08/11/2017	K172122	SOZO	ImpediMed Limited	Gastroenterology-Urology	OBH
07/25/2023	K223473	ME-APDS™; MAGENTIQ-COLO™	Magentiq Eye LTD	Gastroenterology/Urology	QNP
05/19/2023	K231143	GI Genius System 100 and GI Genius System 200	Cosmo Artificial Intelligence - AI, Ltd.	Gastroenterology/Urology	QNP
04/07/2023	K230658	:SKOUT® system	Iterative Scopes Inc.	Gastroenterology/Urology	QNP
03/17/2023	K223073	Allo	Allo, Inc.	Gastroenterology/Urology	DRG
08/12/2022	K213886	SKOUT Software	Iterative Scopes Inc	Gastroenterology/Urology	QNP

From: <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices>



#90159

CE 2797

Metastasis Detection, AI

Certified under IVDR

AI/deep learning-assisted metastasis detection in Lymph nodes – simplifying lymph node assessment.

Approved in the EU, does not currently have FDA approval






Figure 1

All relevant lymph node tissue is automatically outlined (in purple) for further analysis.




Figure 2

Metastases are identified as High Probability (red), Medium Probability (orange), Low Probability (yellow) and the largest is highlighted and measured.

Approved in the EU, does not currently have FDA approval



> [Mod Pathol. 2023 Oct;36\(10\):100285. doi: 10.1016/j.modpat.2023.100285. Epub 2023 Jul 18.](#)

Performance of an Artificial Intelligence Model for Recognition and Quantitation of Histologic Features of Eosinophilic Esophagitis on Biopsy Samples

Luisa Ricaurte Archila ¹, Lindsey Smith ², Hanna-Kaisa Sihvo ³, Ville Koponen ³, Sarah M Jenkins ⁴, Donnchadh M O'Sullivan ⁵, Maria Camila Cardenas Fernandez ⁵, Yaohong Wang ⁶, Priyadharshini Sivasubramaniam ¹, Ameya Patil ¹, Puanani E Hopson ⁵, Imad Absah ⁵, Karthik Ravi ⁷, Taofic Mounajjed ⁸, Evan S Dellon ⁹, Albert J Bredenoord ¹⁰, Rish Pai ¹¹, Christopher P Hartley ¹, Rondell P Graham ¹, Roger K Moreira ¹²

Affiliations + expand

PMID: 37474003 DOI: [10.1016/j.modpat.2023.100285](#)



EoE Paper Background

Often tedious to count eosinophils






GI docs and clinicians want peak eosinophil count (PEC),
also exists: EoEHSS

Study:

Authors had previously developed an AI algorithm using WSI to count eosinophils (supervised deep learning using AI platform (Aiforia))

Prospective study: 203 esophagus bx. With eosinophilia (91 adult and 112 kids) as well as 10 normal controls

Compared results against expert GI pathologist






Figure 2. Artificial intelligence model segmentation layers. A, original hematoxylin and eosin stain; B, model segmentation of lamina propria (red), basal zone (green), dilated intercellular spaces (yellow), and surface layer (blue).





Figure 1. Artificial intelligence model recognition of eosinophilic esophagitis-related segmentation features. A-C, basal zone (green) (A, normal; B, mild to moderate; and C, severe). D-E, dilated intercellular spaces (yellow) (D, mild; E, moderate; F, severe). Lamina propria fibrosis (light green) (G, none; H, mild to moderate; I, severe). Whole slide images, hematoxylin, and eosin stain.

Results

- AI looked at median of 187 HPF areas per biopsy slide
- Inter-rater correlation coefficient between the AI and CP was 0.55
- After AI HPF grid method, increased to 0.96.
- AI model identified 6 of 19 (31.5%) grade 1 cases as grade 2 (≥ 15 eosinophils per HPF).
- Re-review by CP with AI guided identification of the area of highest eosinophil concentration confirmed the presence of 15 eosinophils or greater in **three of the six cases**.



[Download](#) : [Download high-res image \(508KB\)](#)

[Download](#) : [Download full-size image](#)

Figure 4. Bland-Altman plot showing mean differences between pathologists' PEC (A, original pathologist's read, and B, central pathologist's read) and AI model PEC. After recount of PEC (by the central pathologist) based on the location of HPF with highest concentration of eosinophils indicated by the AI model, the mean PEC difference between model and pathologists decreased from 32 eosinophils/HPF to 9.1 and 6.4 eosinophils/HPF (without [C] and with [D] digital dotting tool, respectively). Abbreviations: PEC, peak eosinophil count; SD, standard deviation.





Conclusion

Strong correlation between PEC by the AI model and pathologists.

AI absolute counts were significantly and consistently higher than the pathologists' PEC in both adult and pediatric populations.

Overestimated EAs (could improve accuracy in future versions.)

AI performed similar to GI pathologist

AI assisted identification of PEC “significantly more accurate”



> [Dig Endosc.](#) 2023 Nov;35(7):902-908. doi: 10.1111/den.14547. Epub 2023 Apr 10.

Whole slide image-based prediction of lymph node metastasis in T1 colorectal cancer using unsupervised artificial intelligence

Yuki Takashina¹, Shin-Ei Kudo¹, Yuta Kouyama¹, Katsuro Ichimasa^{1 2}, Hideyuki Miyachi¹,
Yuichi Mori^{1 3}, Toyoki Kudo¹, Yasuharu Maeda¹, Yushi Ogawa¹, Takemasa Hayashi¹,
Kunihiko Wakamura¹, Yuta Enami¹, Naruhiko Sawada¹, Toshiyuki Baba¹, Tetsuo Nemoto⁴,
Fumio Ishida¹, Masashi Misawa¹

Paper: T1 WSI prediction of LN metastasis



When submucosal invasion identified during a polypectomy, it is important to determine if a patient needs a colectomy due to lymph node metastasis risk

Approximately 10% of T1 CRC will have LN mets

Current pathologic features to predict LNM: poor differentiation, tumor budding, lymphovascular invasion

Paper: T1 WSI prediction of LN metastasis



Retrospective single center study

Used 100 each T1 and T2 colon resections

Used 1:1 cohort of LN+ (50) and LN- (50) cases

Used single slide with deepest invasion

1st step) Invasive carcinoma was annotated


2nd step) Pathology images were used to pretrain a convolutional neural network to create a feature extractor

3rd step) Conducted unsupervised training using K-means, a nonhierarchical clustering method--> risk of LNM stratified into 10 categories


Made 10 clusters and calculated the percentage of LNMC positive patches in each cluster

Sex and tumor location also used for LNM prediction


Whole slide image-based prediction of lymph node metastasis in T1 colorectal cancer using unsupervised artificial intelligence



Whole slide image-based prediction of lymph node metastasis in T1 colorectal cancer using unsupervised artificial intelligence



Whole slide image-based prediction of lymph node metastasis in T1 colorectal cancer using unsupervised artificial intelligence



Paper: T1 WSI prediction of LN metastasis



AUC prediction of LNM by the AI was 0.745

Using traditional pathologic scoring: AUC is 0.524

This model could theoretically reduce the rate of surgery by 3.4%

Limitations:

- Single center retrospective design
- Also used T2 cases, which isn't really applicable to polypectomy specimens
- Didn't account for the size of the tumor
- Need to validate this study with an external data set



[BMC Gastroenterol.](#) 2020; 20: 417.

Published online 2020 Dec 11. doi: [10.1186/s12876-020-01494-7](https://doi.org/10.1186/s12876-020-01494-7)

PMCID: [PMC7731757](#)

PMID: [33308189](#)

Deep learning for sensitive detection of *Helicobacter Pylori* in gastric biopsies

[Sebastian Klein](#),^{00#1,2} [Jacob Gildenblat](#),^{#3} [Michaele Angelika Ihle](#),² [Sabine Merkelbach-Bruse](#),² [Ka-Won Noh](#),²
[Martin Peifer](#),⁴ [Alexander Quaas](#),² and [Reinhard Büttner](#)⁰⁰²

▶ [Author information](#) ▶ [Article notes](#) ▶ [Copyright and License information](#) [PMC Disclaimer](#)



> [APMIS](#). 2022 Jan;130(1):11-20. doi: 10.1111/apm.13190. Epub 2021 Nov 22.

Automated assessment of Ki-67 proliferation index in neuroendocrine tumors by deep learning

[Tiina Vesterinen](#)^{1 2}, [Jenni Säilä](#)², [Sami Blom](#)^{1 2 3}, [Mirkka Pennanen](#)¹, [Helena Leijon](#)¹,
[Johanna Arola](#)¹

Affiliations + expand

PMID: 34741788 PMCID: [PMC9299468](#) DOI: [10.1111/apm.13190](#)

Free PMC article

Summary



Prospective digitization of slides needed to perform clinically validated AI algorithms
Most pathologists in the US still use glass slides, but this is evolving
Investment in scanners, IMS, storage, etc.

Currently one FDA approved algorithm (prostate biopsy screening), many more coming in the near future (next 1-2 years)

Generizability of research studies to population at large

Reimbursement?

Pathologist's Efficiency?

QC/QA

Business opportunities with AI and Digital Pathology

What is a clinically validated example of AI an application in GI Path?



- A) Pancreas cancer detection in core biopsies
- B) Metastasis detection within lymph nodes of colorectal cancer resection specimens
- C) Grading of dysplasia in Barrett's esophagus
- D) Lymph node prediction in T1 polypectomy specimens
- E) Eosinophil quantitation in esophageal biopsies

What are current examples of AI applications in GI Path?

Answer:

B) Metastasis detection within lymph nodes of colorectal cancer resection specimens



What are the minimum hardware and software needs to perform clinically validated AI in Surgical Pathology?



What are the minimum hardware and software needs to perform clinically validated AI in Surgical Pathology?



WSI scanners

Image management software

PACS (picture archiving and communication system)

Validated AI software



Questions?





References

Baxi et al. “Digital Pathology and artificial intelligence in translational medicine and clinical practice” *Modern Pathology* (2022) 35:23-32

Aeffner et al. “Introduction to digital image analysis in whole-slide imaging: a white paper from the digital pathology association” *J. Pathol. Inf.* 10, 9 (2019)

Bera K. et al. “Artificial Intelligence in digital pathology-new tools for diagnosis and precision oncology” *Nat. Rev. Clin. Oncol.* 16, 703-715

ClinicalTrials.gov. Bethesda (MD) National Library of Medicine Identifier NCT03698461, Treatment of colorectal liver metastases with immunotherapy and bevacizumab (CLIMB); 2018 Oct 9.



References continued

Kim H.-N. et al. "PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation" *Virchows Arch.* 476, 243-250 (2020).

Abels et al. "Computational pathology definitions, best practices, and recommendations for regulatory guidance: a white paper from the Digital Pathology Association. *J. Pathol.* 249, 286-294 (2019).

Pages et al. "International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet* 391, 2128-2139 (2018).

Lui et al. "Applications of Artificial Intelligence in Breast Pathology" *Arch. Pathol. Lab Med.* 147, September 2023



References continued

Archila et al. "Performance of an Artificial Intelligence Model for Recognition and Quantitation of Histologic Features of Eosinophilic Esophagitis on Biopsy Samples" *Mod Pathol* 2023 Oct;36 36 (10)

Yoshida, H. et al. "Requirements for implementation of artificial intelligence in the practice of gastrointestinal pathology" *World J Gastroenterol* 2021 June 7; 27(21): 2818-2833

Yousif et al. "Artificial Intelligence-Enabled Gastric Cancer Interpretations: Are We There Yet?" *Surgical Pathology Clinics*, Volume 16, 673-686, 2023

<https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices>



University of Nebraska Medical Center™

BREAKTHROUGHS FOR LIFE.®

UNIVERSITY OF
Nebraska
Medical Center